Fortis follows a formal recruitment process through its HR department that entails on-site meetings. We do not demand or accept any monetary consideration from any individual against an offer letter or appointment or as a part of the recruitment process.Click Here | As per the GOI circular on price capping of Orthopaedic Knee implant by NPPA(National Pharmaceutical Pricing Authority), new prices of knee implants have been implemented effective 16th August 2017. For details on knee implant pricing across our hospitals.Click Here. | As per GOI’s circular dated 29th March 2019 on price-capping of stents by NPPA (National Pharmaceutical Pricing Authority), new prices of coronary stents are revised with effect from 01st April 2019. For details on stent pricing,Click Here | As per GOI Notification No. 03/2022 - Central Tax (Rate), GST of 5% is applicable* on all room charges exceeding Rs. 5000 per day (with the exception of ICU), for receiving treatment within our hospitals. (*On all discharges starting 18th July, 2022)

Fortis Hospitals Mumbai launch first-of-its-kind ‘Advanced OncoSurgery Unit’ across its network in Mumbai

16th September 2021, Mumbai: The pandemic posed innumerable challenges on Cancer patients across the nation. Even today, Cancer Care services, function with a lot of disruption, causing patients to pay a heavy price for delayed treatment. Fortis Hospitals Mumbai has introduced a protocolised and state-of-the-art Advanced OncoSurgery Unit (AOU) that would offer high-quality, uninterrupted Cancer Care for the people of Mumbai and its neighbouring cities.

Dr. S Narayani, Zonal Director, Fortis Hospitals Mumbai, and Dr. Anil Heroor, Director Advanced OncoSurgery Unit, Fortis Hospitals Mumbai, inaugurated the AOU today. It will offer patients value and protocol-based surgical care. Chaired by Dr. Anil Heroor, his team of surgical experts includes Dr. Hitesh R Singhavi (Consultant-Head & Neck Surgery), Dr. Nikhil Darmadhikari (Consultant-Surgical Oncology), Dr. Rahulkumar Chavan (Consultant-Surgical Oncology) and Dr. Tejas Savdekar (Associate Consultant), who will offer oncosurgical care with top end technology across Fortis Hospital, Mulund, Hiranandani Hospital, Vashi, SL Raheja Hospital, Mahim & Fortis Hospital, Kalyan.

Through this launch, standardised surgical Cancer Care will be offered across all corners of the city, making care uniformed, accessible, and affordable. These AOU Team will function in perfect tandem to focus all synergies to drive the program across all four hospitals in Mumbai.

Dr. Anil Heroor, Director-Advanced OncoSurgery Unit, Fortis Hospitals Mumbai, said, “This is indeed a milestone, as we adopt a uniform patient centric approach across all our hospitals in Mumbai. This will strengthen the services offered by my team, and provide personalised care basis the patients’ requirements, affordability, and need for surgical intervention. Our OncoSurgery units across the city are focused towards providing safe and precision-oriented care. Spread across Mumbai, our OncoSurgery units are equipped with state-of-the-art technology right from the world’s most advanced ‘da Vinci Xi’ robotic surgical system, to the linear accelerator (for radiation therapy)”.

Fortis Hospital Mulund is also accredited as National Board for Cancer Surgical Training & Research. Thus, all centres across Mumbai will be able to harness the clinical and research capabilities centrally. Moreover, Fortis Hospitals Mumbai also has a ‘Tumour Board’ that will enable all Cancer specialists across the centres to provide expert option about complicated cases. Through this initiative, the hospital chain will also increase screening services across the city.

Dr. S Narayani, Zonal Director, Fortis Hospitals, Mumbai, said, “Cancer treatment when done in the early stages has immense success rates; timely diagnosis & intervention is the key to combating Cancer. In the past 18 months, many patients with Cancer, and their families have had to pay a heavy price due to delayed treatment, owing to the global public health emergency. COVID19 also increased mortality rates among patients with active Cancer or those who have had a history of Cancer in the past five years. At Fortis Hospitals Mumbai, we needed to take progressive steps to ensure that patients received the necessary care at the right time, without any disruption. We are extremely proud to launch this program across all our hospitals across Mumbai. This initiative is our promise to offer uninterrupted, protocolised, and personalised surgical care to all patients”. --

About Fortis Healthcare Limited:
Fortis Healthcare Limited – an IHH Healthcare Berhad Company – is a leading integrated healthcare services provider in India. It is one of the largest healthcare organisations in the country with 36 healthcare facilities (including projects under development), 4000 operational beds and over 400 diagnostics centres (including JVs). Fortis is present in India, United Arab Emirates (UAE) & Sri Lanka. The Company is listed on the BSE Ltd and National Stock Exchange (NSE) of India. It draws strength from its partnership with global major and parent company, IHH, to build upon its culture of world-class patient care and superlative clinical excellence. Fortis employs 23,000 people (including Agilus Diagnostics Limited (Formerly Know as Agilus Diagnostics Limited (Formerly Know as SRL Limited) Limited)) who share its vision of becoming the world’s most trusted healthcare network. Fortis offers a full spectrum of integrated healthcare services ranging from clinics to quaternary care facilities and a wide range of ancillary services.



Or Give A Missed Call to

Request An Appointment